AstraZeneca
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, AstraZeneca sits in the top decile of US sponsors by registered trial count (#20 of 15,742 sponsors by registered trial count).
AstraZeneca: 1,285 sponsored US clinical trials, 160 recruiting.
AstraZeneca sponsors 1,285 registered US clinical trials on ClinicalTrials.gov, 160 of them currently recruiting, and 883 completed. 484 of these trials are in Phase 3-4 (later-stage) and 720 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Non-Small Cell Lung Cancer, with 24 trials.
Top-decile sponsor footprint
AstraZeneca ranks in the top decile of sponsors by registered trial count (#20 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
883 of 987 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (89.5%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
1,285 total, page 18 of 26
Effects of Administration of Fostamatinib on Blood Concentrations of Pioglitazone in Healthy Subjects
NCT01309854
Assessment of Efficacy and Safety in Patients With Non-cancer-related Pain and Opioid-induced Constipation
NCT01309841
Multiple Ascending Doses of AMG 139 in Healthy and Crohn's Disease Subjects
NCT01258205
A Safety Study to Assess the Effects of Therapeutic and Supratherapeutic Exenatide Concentrations on QT Interval in Healthy Subjects
NCT01297062
A Study to Assess the Safety and Effect of TC-5214 in Patients With Major Depressive Disorder.
NCT01288079
Randomised Double-Blind, Placebo-Controlled, Parallel Group Study in Patients With Active Rheumatoid Arthritis:Magnetic Resonance Imaging Sub-Study
NCT02092961
Epanova® for Lowering Very High Triglycerides
NCT01242527
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
NCT01242514
Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)
NCT01264770
A Study To Examine The Efficacy And Safety Of Pramlintide+Metreleptin In Obese Subjects
NCT01235741
Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules
NCT01226316
A Phase IIa Study to Assess the Tolerability, Safety, and Efficacy of AZD4017 for Raised Intra-ocular Pressure
NCT01173471
To Compare the Pharmacokinetics of a Single Oral Dose of TC-5214 in Subjects With Renal Impairment and With Subjects With Normal Renal Function
NCT01240967
An Open-Label, Dose-Escalation Study of AZD2461
NCT01247168
A Study of Fostamatinib in Subjects With Impaired Kidney Function
NCT01245790
A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics After High Single Ascending Oral Doses of AZD1656 in T2DM Patients
NCT01221545
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
NCT01195662
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
NCT01225562
Investigation of Efficacy, Safety and Tolerability of Once and Twice Daily Doses of AZD1981 in Asthmatic Patients
NCT01197794
A Study of Fostamatinib in Subjects With Impaired Hepatic (Liver) Function
NCT01222455
Epanova® Compared to Lovaza® In a Pharmacokinetic, Single-dose, Evaluation
NCT01208961
A Study in Asthmatic Children (6 to <12 Yrs) Comparing Single Doses of Formoterol and Foradil® Evaluating Efficacy
NCT01136655
Study in Healthy Males to Assess Bioavailability of 4 Different Fostamatinib Tablets
NCT01208155
A Study to Investigate the Analgesic Efficacy of AZD2423 Compared With Placebo After 28 Days Treatment in Patients With Painful Diabetic Polyneuropathy
NCT01201317
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Disease Modifying Anti-rheumatic Drug (DMARD) But Not Responding.
NCT01197534
Study to Evaluate the Interaction Between Aspirin and Nexium
NCT01199328
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Not Responding.
NCT01197521
Evaluation of the Drug-drug Interaction Between FosD and Verapamil When Taken Together in Healthy Volunteers
NCT01197781
Zomig - Treatment of Acute Migraine Headache in Adolescents
NCT01211145
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
NCT01197755
A Relative Bioavailability Study Measuring the Extent and Rate of Absorption of Different Tablet Formulations of AZD1656 in Type 2 Diabetes Mellitus (T2DM) Patients
NCT01221519
Open Label Prostate Cancer Study
NCT01162395
Characterization of the Kinetics of Renal Glucose Reabsorption in Response to Dapagliflozin in Healthy Subjects and in Subjects With Type 2 Diabetes Mellitus (T2DM)
NCT01165268
Single Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD4451
NCT01196676
A 6-week Study in Asthmatic Children Aged 6 to <12 Yrs Comparing Budesonide pMDI 160ug Twice Daily With Placebo
NCT01136382
Study to Investigate Multiple Ascending Oral Doses of AZD5213 in Healthy Male and Non Fertile Female Subjects
NCT01171105
To Assess Safety, Tolerability, Pharmacokinetics/Pharmacodynamics and the Effect of Fasting After Single Oral Doses of AZD5658 in Type 2 Diabetes
NCT01176097
A Study to Assess the Safety, Tolerability, and Blood and Urine Drug Levels of Fostamatinib Disodium (FosD) in Healthy Japanese and White Subjects
NCT01167868
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes and Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker
NCT01137474
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus
NCT01144338
To Investigate the Safety and Tolerability of TC-5214 Following Oral Administration of Multiple Doses for up to 8 Days
NCT01145768
A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder
NCT01153347
A Study to Assess the Long- Term Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder
NCT01152554
Food Interaction Study To Assess the Effect of Food on the Pharmacokinetics of Esomeprazole 20 mg/Acetylsalicylic Acid 81 mg
NCT01163630
Assessing the Safety and Tolerability of a Single IV Dose of AZD9742 in Healthy Elderly Male and Female Subjects
NCT01154621
A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder (MDD)
NCT01157078
Investigate the Effect of AZD1656 on the Pharmacokinetics of Digoxin in Type 2 Diabetes Mellitus Patients
NCT01103622
Oral AZD8165 After Single Oral Ascending Doses in Healthy Male Subjects
NCT01150812
Study of Anastrozole +/- AZD8931 in Postmenopausal Women With Endocrine Therapy Naive Breast Cancer
NCT01151215
Study to Investigate Single Ascending Oral Doses of AZD5213 in Healthy Male and Non Fertile Female Subjects
NCT01121302
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 444 |
| Phase 2 | 276 |
| Phase 3 | 437 |
| Phase 4 | 47 |
Therapeutic Areas
What is open in the AstraZeneca pipeline
160 recruiting of 1,285 indexed (12% open); 883 completed (69%).
Phase mix: 484 late (III/IV) vs 720 early (I/II) (balanced across stages).
Top condition: Non-Small Cell Lung Cancer (24 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
AstraZeneca: open-pipeline peers nationwide
Peers matched on 1,285 registered trials and 12% open enrollment, not the therapeutic-area sidebar.
AstraZeneca sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 1,285 trials (± recruiting share)
- University of Colorado, Denver · 1,283 trials · 21% recruiting
- University of Michigan · 1,327 trials · 13% recruiting
- University of Pittsburgh · 1,238 trials · 13% recruiting
- Eli Lilly and Company · 1,341 trials · 9% recruiting
Sponsors near 12% open enrollment (± trial volume)
- Boston University · 12% recruiting · 185 trials
- Addario Lung Cancer Medical Institute · 13% recruiting · 8 trials
- American University · 13% recruiting · 16 trials
- Annexon · 13% recruiting · 8 trials
Related
What to do with this AstraZeneca page
1,285 registered trials is a research-attention snapshot, not an endorsement of AstraZeneca or any single study.
- 160 of AstraZeneca's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Non-Small Cell Lung Cancer is the condition AstraZeneca studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Non-Small Cell Lung Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. AstraZeneca pipeline card: 1,285 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.